

# Bölüm 5

## PENİSİLİN AŞIRI DUYARLILIĞI OLAN HASTALARDA ENDOKARDİT PROFİLAKSİSİ

Begüm GÖRGÜLÜ AKIN<sup>1</sup>

### İnfektif Endokardit

#### Tanımı, Sıklığı ve Risk Faktörleri

İnfektif endokardit (İE), sık görülmeyen, ancak yol açtığı morbiditeler ve yüksek ölüm hızı nedeniyle halen önemli bir infeksiyon hastalığıdır. Gelişmiş ülkelerde İE sıklığı yaklaşık 6/100.000 kişidir (1, 2). Ülkemizde akut romatizmal ateş (ARA) ve romatizmal kalp kapak hastalığı sık görülmesi nedeniyle İE gelişmiş ülkelere göre daha sık görülmektedir. İnfektif endokardit genellikle sol kalp kapaklarını etkilemektedir. İnfektif endokardit riskinin arttığı durumlar Tablo 1’de verilmiştir.

<sup>1</sup> Uzm. Dr. Ankara Şehir Hastanesi, Alerji ve Klinik İmmünoloji, drbegumgorgulu@gmail.com

## Sonuç

İnfektif endokardit, yönetimi zor ve karmaşık bir hastalıktır. Profilaksisi için beta laktam alerjisi yoksa penisilin veya sentetik penisilinler ilk seçenek olan ilaçlardır. Penisilin allerjisi olan hastalarda alternatif antibiyotik seçenekleri denenebilir. Ancak alternatif tedaviler yetersiz ve etkisiz olduğunda penisilin ile desensitizasyon yapılması düşünülebilir.

## KAYNAKLAR

1. Şimşek-Yavuz S, Akar AR, Aydoğdu S, et al. İnfektif endokarditin tanısı, tedavisi ve önlenmesi: Ulusal uzlaşma raporu. *KLİMİK Dergisi*. 2019;32(1):2.
2. Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *Journal of the American College of Cardiology*. 2015;65(19):2070-6.
3. Tleyjeh IM, Abdel-Latif A, Rahbi H, et al. A systematic review of population-based studies of infective endocarditis. *Chest*. 2007;132(3):1025-35.
4. de Sa DDC, Tleyjeh IM, Anavekar NS, et al. Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota. *Mayo Clinic Proceedings*; 2010: Elsevier.
5. Fowler VG, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. *Jama*. 2005;293(24):3012-21.
6. Selton-Suty C, Célard M, Le Moing V, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. *Clinical infectious diseases*. 2012;54(9):1230-9.
7. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. *Circulation*. 2015;132(15):1435-86.
8. Flynn CD, Curran NP, Chan S, et al. Systematic review and meta-analysis of surgical outcomes comparing mechanical valve replacement and bioprosthetic valve replacement in infective endocarditis. *Annals of cardiothoracic surgery*. 2019;8(6):587.
9. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American heart association: a guideline from the American heart association rheumatic fever, endocarditis, and Kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. *Circulation*. 2007;116(15):1736-54.
10. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. 2014;63(22):e57-e185.
11. Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. *Current opinion in infectious diseases*. 2012;25(2):145-53.

12. Steer AC, Kado J, Colquhoun S, et al. Awareness of rheumatic heart disease. *The Lancet*. 2006;367(9528):2118.
13. Abubakar I, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385(9963):117-71.
14. Zühlke LJ, Steer AC. Estimates of the global burden of rheumatic heart disease. *Global heart*. 2013;8(3):189-95.
15. Gray L-A, D'Antoine HA, Tong SY, et al. Genome-wide analysis of genetic risk factors for rheumatic heart disease in aboriginal Australians provides support for pathogenic molecular mimicry. *The Journal of infectious diseases*. 2017;216(11):1460-70.
16. Johnson DR, Kurlan R, Leckman J, et al. The human immune response to streptococcal extracellular antigens: clinical, diagnostic, and potential pathogenetic implications. *Clinical infectious diseases*. 2010;50(4):481-90.
17. Webb RH, Grant C, Harnden A. Acute rheumatic fever. *Bmj*. 2015;351.
18. Celik G, Büyüköztürk S, Sin A, et al. İlaç aşırı duyarlılık reaksiyonlarına yaklaşım. Ulusal rehber Ankara: Bilimsel Tıp Yayınevi. 2014.
19. Mirakian R, Leech S, Krishna M, et al. Management of allergy to penicillins and other beta-lactams. *Clinical & Experimental Allergy*. 2015;45(2):300-27.
20. Magpantay G, Cardile AP, Madar CS, et al. Antibiotic desensitization therapy in secondary syphilis and Listeria infection: case reports and review of desensitization therapy. *Hawaii Medical Journal*. 2011;70(12):266.
21. Sullivan TJ, Yecies LD, Shatz GS, et al. Desensitization of patients allergic to penicillin using orally administered  $\beta$ -lactam antibiotics. *Journal of Allergy and Clinical Immunology*. 1982;69(3):275-82.
22. Stark BJ, Earl HS, Gross GN, et al. Acute and chronic desensitization of penicillin-allergic patients using oral penicillin. *Journal of allergy and clinical immunology*. 1987;79(3):523-32.
23. Wendel Jr GD, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. *New England Journal of Medicine*. 1985;312(19):1229-32.
24. Solensky R, Feldweg A. Penicillin allergy: immediate reactions. *UpToDate*. 2019.
25. Chastain DB, Hutzley VJ, Parekh J, et al. Antimicrobial desensitization: A review of published protocols. *Pharmacy*. 2019;7(3):112.
26. Castells M. Rapid desensitization for hypersensitivity reactions to medications. *Immunology and allergy clinics of North America*. 2009;29(3):585-606.
27. del Carmen Sancho M, Breslow R, Sloane D, et al. Desensitization for hypersensitivity reactions to medications. *Adverse Cutaneous Drug Eruptions*. 97: Karger Publishers; 2012. p. 217-33.
28. Wurpts G, Aberer W, Dickel H, et al. Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics. *Allergo Journal International*. 2019;28(5):121-51.